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doi:10.1016/j.ejvs.2009.05.022Abstract Background: Although warfarin is routinely stopped prior to varicose vein surgery
the absence of incisions may make this unnecessary prior to EVLA. Nevertheless continuing
therapy may compromise ablation rates resulting in treatment failure. Since EVLA is particu-
larly suitable for older patients with co-morbidities this study investigates whether warfarin
influences outcome.
Method: A prospective observational cohort study was designed to assess ablation rates
(1 year, duplex ultrasound), Aberdeen varicose vein symptom severity scores (AVVSS) and
patient satisfaction following GSV EVLA in 22 patients (‘‘warfarin group’’: 12 female, 10 male;
24 limbs) taking warfarin and 24 age/sex and disease-severity matched controls who were not
taking anticoagulants (‘‘no-warfarin group’’).
Results: Complete ablation of the treated-length of GSV was achieved in 20/24 (83%) limbs in
the ‘‘warfarin group’’ versus 23/24 (96%) in the ‘‘no-warfarin’’ group (pZ 0.347, chi squared).
Suboptimal energy densities were delivered to 3/4 failures in the ‘‘warfarin group’’. A similar,
significant (p< 0.001, Wilcoxon) improvement in AVVSS occurred in both groups [warfarin:
median 14.6 (inter-quartile range 8.9e19.1) to 3.8 (1.9e6.2), no-warfarin: median 13.9 (IQR
7.6e20.1) to 3.5 (2.2e6.4)]. Patients were equally satisfied with outcomes (warfarinZ 92%,
no-warfarinZ 90%; pZ 0.391, ManneWhitney). No major complications occurred.
Conclusions: EVLA in patients taking warfarin is safe and effective. Since cessation of therapy
is unnecessary it should provide a valuable alternative to surgery in these patients.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Tel.: þ44 113 3922823; fax:
edsth.nhs.uk (M.J. Gough).
ty for Vascular Surgery. PublisheIntroduction
Endovenous laser ablation (EVLA) employs thermal energy
to cause irreversible vein wall injury leading to occlusion of
an incompetent great, small or anterior accessory saphe-
nous vein in the treatment of varicose veins. Previous
studies have shown that laser energy density is the singled by Elsevier Ltd. All rights reserved.
EVLA in Patients Taking Warfarin 507most important factor that determines the efficacy of laser
ablation.1,2
In the short term it is likely that thrombotic occlusion of the
treated vein occurs before vein contraction and fibrosis
ensues. Thus it is possible that factors that inhibit thrombus
formation such as anticoagulants may influence the success of
EVLA.
Unlike surgery, EVLA may be particularly suitable for
older patients and those with significant medical co-
morbidities in whom the treatment of superficial venous
reflux and varicose veins is indicated because of compli-
cations such as varicose eczema, lipodermatosclerosis and
ulceration. A proportion of these patients may be
prescribed long term anticoagulants such as warfarin for
their co-existent medical conditions. Such drugs would
usually be stopped prior to conventional varicose vein
surgery because of the risk of intra-operative bleeding.
Further, in-patient as opposed to day-case surgery is usually
required with the duration of admission prolonged if pre-
operative conversion to heparin therapy is needed or post-
operative stabilisation of anticoagulant therapy necessary.
A potential advantage of EVLA, given the absence of
surgical incisions, is that anticoagulant therapy may not
need to be stopped before undertaking EVLA although this
might influence the success of axial vein ablation. This
study therefore assesses the influence of warfarin on the
outcome of EVLA.Methods
Patients
Of 393 patients who underwent EVLA for varicose veins
between May 2005 and January 2007 at the Leeds Vascular
Institute, 22 patients (median age 62 years, range 51e77),
12 female, 10 male; 24 limbs, continued taking warfarin at
the time of treatment (‘‘warfarin group’’) for varicosities
secondary to sapheno-femoral junction (SFJ) and GSV
reflux. Outcomes in these patients were compared with
those for 24 age/sex and disease-severity (CEAP) matched
control patients (‘‘no-warfarin group’’) who were not
taking warfarin. The control patient for each study patient
was the next ageesex and disease-severity matched
patient undergoing EVLA and who subsequently completed
1 year follow-up. Patients with concomitant reflux in both
the small saphenous vein and GSV and those with a previous
deep vein thrombosis (DVT) were excluded from the study.
The indication for warfarin therapy in the study group was
atrial fibrillation (nZ 14) or a metallic heart valve (nZ 8).
Informed consent was obtained from all patients for the
both EVLA and data collection.Data collection
Prior to laser treatment all patients underwent a duplex
ultrasound scan (DUS) [TITAN, Sonosite Inc, Bothell, USA,
5e10 MHz linear probe] to confirm the site of superficial
venous incompetence and the diameter of the GSV was
recorded 10 cm distal to the SFJ, avoiding any localised
dilatation. Suitability for GSV EVLA was established usingcriteria that have been described previously.1 Patients’
past medical history and drug history were documented.
Disease severity was assessed using ‘‘C’’ of the CEAP
clinical classification4 (‘‘EAP’’ of CEAP were the same for all
patients). Disease specific quality of life was assessed using
the Aberdeen varicose vein symptom severity score (AVVSS)
before and 1 year after EVLA.
EVLA was performed using an 810 nm diode pulsed laser
at 12 W power and tumescent local anaesthesia (0.1%
lignocaine) as described previously.1 Neither concomitant
phlebectomies nor foam sclerotherapy was undertaken
although the latter was performed for residual varicosities
at the first follow-up visit (6 weeks) if requested by the
patient. Treatment details including the laser energy
density (J/cm) were documented.
During follow-up patients were assessed at 6, 12 and 52
weeks for clinical signs of recurrence and successful GSV
ablation (duplex ultrasound). The criteria for successful
ablation have been described previously.3 Patient satis-
faction was assessed at 1 year using a 10 cm visual analogue
scale which was then calculated as a percentage. A
prospective log of complications was maintained
throughout the study. These included deep vein thrombosis
(DVT), phlebitis, nerve damage (sensor or motor), chronic
pain, and skin pigmentation. These were assessed clinically
and for DVT by ultrasound. All data were collected
prospectively by a consultant vascular surgeon or vascular
research fellow. This is a prospective observational cohort
study with two groups.
Statistical analysis
All datawere tested for normal distribution andare presented
asmedian (inter-quartile range, IQR) unless stated otherwise.
The AVVSS before and after laser ablation were compared
within a group using a Wilcoxon test and the improvements in
AVVSS between groups were compared by a ManneWhitney
U test. A chi squared test was used for contingency table
analysis. All analyses were performed using the statistical
packageSPSS forWindows (SPSS (14), Chicago, Illinois, USA).
Results
Disease severity and the demographic data of the two
groups are summarised in Table 1. Pre-treatment vein
diameters were similar in both groups (Table 2). Successful
occlusion of the full length of the treated GSV was observed
in 20/24 (83%) limbs in the ‘‘warfarin group’’ compared to
23/24 (96%) limbs in the ‘‘no-warfarin group’’ (pZ 0.347,
chi squared). Although the overall laser dose was not
significantly different between the two groups, of the four
patients in whom successful ablation was not achieved in
the ‘‘warfarin group’’, three patients had received subop-
timal laser energy densities (46, 44, and 52 J/cm). In these
patients the GSV was patent and compressible on ultra-
sound examination at 6 weeks suggesting primary failure
due to inadequate treatment. The most recent INR was
recorded in 2/3 of these patients and was 2.7 and 3.1. For
the group as a whole the range in INR was 2.3e4.1 and this
suggests that the INR level was not an important factor in
these treatment failures. Small numbers preclude formal
Table 1 Demography and CEAP classification of patients undergoing EVLA (CEAP score: clinical, etiology, anatomy, pathology)
Characteristics ‘‘Warfarin group’’ (%) ‘‘No-warfarin group’’
(age/sex/disease
severity matched)
(%)
Male 10 (45%) 10 (45%)
Female 12 (55%) 12 (55%)
Age, median (range) 62 (51e77) years 62 (51e77) years
Number of limbs treated 24 24
CEAP
C2 13 (54%) 13 (54%)
C3 4 (17%) 4 (17%)
C4 4 (17%) 4 (17%)
C5 2 (8%) 2 (8%)
C6 1 (4%) 1 (4%)
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62 J/cm laser energy the GSV was partially occluded at 6
week follow-up but was fully patent with reflux at 12
weeks. This is more likely to represent recanalisation.
Similarly, the patient in whom treatment failed in the ‘‘no-
warfarin group’’ received 58 J/cm laser energy, had
a partially occluded vein at 6 weeks but a recanalised GSV
at 12 weeks. These data are summarised in Table 2.
A significant improvement in AVVSS occurred in both
groups: ‘‘warfarin group’’: median 14.6 (IQR 8.9e19.1) to
3.8 (1.9e6.2), ‘‘no-warfarin group’’: median 13.9 (IQR 7.6e
20.1) to 3.5 (2.2e6.4); p< 0.001, Wilcoxon. However, there
was no difference in either the improvement between the
groups (pZ 0.446, ManneWhitney) or in patient satisfac-
tion (AZ 92% versus BZ 90%, pZ 0.391, ManneWhitney).
There were no instances of DVT in either group and only
one patient in the ‘‘no-warfarin group’’ reported marked
post-EVLA discomfort (‘‘phlebitis’’). None of the patients
described either extensive bruising or haematoma formation.
Details of subsequent treatment and their outcome for
patients with either primary treatment failure or recanali-
sation are shown in Table 2.Discussion
Unlike conventional surgery, EVLA ablates the target
incompetent axial vein in-situ without the need for surgical
incisions. When varicose vein surgery is performed in
patients who are taking anticoagulants such as warfarin it is
common practise to discontinue therapy 3 days (with or
without heparin cover) prior to operation. The results of
this study show that EVLA remains effective in most
patients who continue to take warfarin throughout the
treatment period. Although there were more treatment
failures in warfarin patients it seems likely that this was
associated with suboptimal laser energy delivery in most
instances although a larger study would be required to
confirm this. Nevertheless it is possible that warfarin might
have contributed to these failures and thus it is reasonable
to conclude that a laser energy density 60 J/cm1,2 is
required in these patients. Even if warfarin therapy was the
primary reason for these treatment failures successful
ablation occurred in the majority of patients thus justifyingboth the adoption of this technique in these patients and
the continuation of anticoagulant therapy.
Adiode laserof810 nmwavelengthproduces temperatures
above 700 C at the tip of the laser fibre.4 Nevertheless the
temperature recorded 3 mm from the vein wall in the
surrounding tumescent anaesthesia is only 43 C.5 It is there-
fore clear that the veinwall absorbs a significant proportion of
the thermal energy that is delivered. Although Proebstle et al6
suggested thatheat conduction fromthe laserfibre to the vein
wall is the result of steam bubble formation in blood a more
recent study suggests that direct contact between the fibre
and the vein is the most likely mechanism of action.7 These
high temperatures result in a range of injuries to the vein
including denaturation of protein, tissue desiccation,
necrosis, and possibly carbonisation with charring depending
on the temperature to which it is exposed.7,8 This type of
transmural damage results in a progressive fibrosis and
permanent occlusion of the vein rather than a temporary
thrombotic occlusion7,9 and previous studies have provided
ultrasound-based evidence for this.3,4 Data from the present
study confirm that these same changes occur in patients who
undergo EVLA whilst taking warfarin (Fig. 1). Thus anticoag-
ulants do not appear to interfere with the fibrotic occlusion
that occurs following EVLA.
Currently there are no reports describing the outcome of
other minimally invasive therapies in patients receiving anti-
coagulants. A recent study suggests that foam sclerotherapy
only inflicts patchy endothelial damage and minimal sub-
endothelial injury.10 Thus thrombotic occlusion is likely to be
a major component of its success and anticoagulants could
prevent this. Further studies are required to assess the impact
of warfarin on this and radiofrequency ablation.
Although EVLA avoids surgical incisions peri-venous
bruising may occur in some patients, presumably related to
vein wall perforation following direct contact with the laser
fibre or from the tumescent needle. Thus warfarin could
result in more extensive bruising or haematoma. This did not
seem to be the case in the present study. Although the
extent of bruising was not quantified patient satisfaction was
no different to that in patients who were not on warfarin.
Given that EVLA appears an effective therapy for
superficial venous incompetence in patients taking warfarin
the longer hospital stay associated with conventional
surgery in anticoagulated patients can be avoided. This will
Table 2 Treatment details, ablation status and presence of significant reflux (>1 s) in patients with treatment failure at 6, 12 and 52 week follow-up compared to patients
who had successful treatment in the warfarin and no-warfarin groups
Patient/group Laser energy
(J/cm)
Total laser energy
(J)
DUS findings (ablation status, reflux status and diameter)
Pre-EVLA 6 weeks 12 weeks 52 weeks
Warfarin (1) 46a 1380 Patent, reflux,
7.6 mm
Patent, reflux,
7.4 mm
Patent, reflux,
7.6 mm
Patient had successful
re-do EVLA at 6 m
Warfarin (2) 44a 1408 Patent, reflux,
8.2 mm
Patent, reflux,
8.3 mm
Patent, reflux,
8.1 mm
Patient had successful
re-do EVLA at 7 m
Warfarin (3) 52a 1456 Patent, reflux,
7.7 mm
Patent, reflux,
7.9 mm
Patent, reflux,
7.6 mm
Patient had successful
re-do EVLA at 13 m
Warfarin (4) 62 2260 Patent, reflux,
8.4 mm
Partially occluded,
7.8 mm
Patent, reflux,
5.1 mm
Patient had successful
re-do EVLA at 18 m
No-warfarin (1) 58 2320 Patent, reflux,
7.3 mm
Partially occluded,
7.0 mm
Patent, reflux,
4.3 mm
Patient had successful
DUS guided foam
sclerotherapy at 12 m
Warfarin group:
median (IQR)
64 (54e72) 1997 (1686e2350) Patent, reflux,
7.9 2.1
Fully occluded,
5.0 1.4
Fully occluded,
3.1 1.3
Fully ablated, GSV
not visible
No-warfarin group:
median (IQR)
66 (55e74) 2016 (1640e2460) Patent, reflux,
7.6 2.2
Fully occluded,
5.2 1.5
Fully occluded,
3.0 1.4
Fully ablated, GSV
not visible
p (warfarin versus
no-warfarin)
0.09 0.15 0.19 0.21 0.24 e
a Three patients in the warfarin group received suboptimal laser energy density(<60 J/cm)1,2 for their initial treatment.
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Figure 1 Sequential ultrasound appearance of GSV in a patient from the ‘‘warfarin group’’ after successful EVLA. These changes
are identical to those occurring in patients who are not anticoagulated.3 (A) GSV pre-EVLA (9.2 mm, hypo-echoic, compressible).
(B) GSV 6 weeks post-EVLA (8.5 mm, hypo-echoic, non-compressible, vein occluded). (C) GSV 12 weeks post-EVLA (3.6 mm,
iso-echoic, not compressible, vein ablated). (D) GSV 1 year post-EVLA (not visible e arrow shows empty saphenous space).
510 N.S. Theivacumar, M.J. Goughinevitably improve the cost effectiveness of treatment in
these patients. Further, since patients who are taking
warfarin are generally older and less fit than the majority of
those requesting treatment for varicose veins the risks of
intervention should be reduced. This may be particularly
important given that these patients are more likely to
require treatment for complications of their venous
disease. That this is the case is reflected by a relatively high
proportion of patients classified as C3eC6 in this study.
In conclusion, EVLA in patients who continue to take
warfarin is safe and effective. Although warfarin can be
continued during EVLA, adequate laser energy density or
fluence should be administered to ensure a satisfactory
outcome.Conflict of Interest/Funding
None.
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